Exdensur (depemokimab-ulaa) is an ultra-long-acting biologic therapy indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adults and adolescents aged 12 years and older. It is administered as a subcutaneous injection every six months in addition to standard asthma medications to help reduce the frequency of asthma exacerbations.
It is a monoclonal antibody that antagonizes interleukin-5 (IL-5), a key cytokine involved in eosinophil production and survival. By blocking IL-5 signaling, Exdensur reduces eosinophil-driven inflammation in the airways, helping prevent severe asthma attacks in patients with type 2 inflammation.
Exdensur is not indicated for relief of acute bronchospasm or sudden asthma symptoms and must be administered by a healthcare provider.
